The company's lead candidate, TA-46, is a protein therapy in development for achondroplasia, and they also have a pipeline of therapeutics for rare gastrointestinal and musculoskeletal disorders, including apraglutide, a synthetic peptide analog being evaluated in clinical trials for the treatment of short bowel syndrome. Therachon is a clinical stage biopharmaceutical company headquartered in Switzerland with research labs in France.